Vital Signs - Next-Generation Sequencing Services Market: An Expanding Role in Clinical Applications Opens New Markets
This issue of Vital Signs, released on March 30, 2012, provides a strategic insight on the next-generation sequencing services market. Additionally, a company spotlight is provided for Foundation Medicine. Founded in 2010, the cancer diagnostics firm aims to transform cancer care by including comprehensive molecular analysis of tumors from next-generation sequencing to the diagnostic process. Reimbursement and regulatory news from the FDA is also provided for week of March 12, 2012.
Click headings to expand and collapse
Published: 30 Mar 2012
Tools
Features of this research
Help Desk
For more information and general enquiries, contact Frost & Sullivan near you.
Select a location near you..